Drug Profile
ES 12
Latest Information Update: 20 May 2003
Price :
$50
*
At a glance
- Originator Exocell
- Class
- Mechanism of Action Glycosylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetic complications
Most Recent Events
- 20 May 2003 No development reported - Preclinical for Diabetic complications in USA (unspecified route)
- 23 Aug 1999 ES 12 is available for licensing
- 23 Aug 1999 Preclinical development for Diabetic complications in USA (Unknown route)